# INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

> **NCT07224321** · PHASE2 · RECRUITING · sponsor: **Mannkind Corporation** · enrollment: 100 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Technosphere Insulin
- **DRUG:** Technosphere Insulin
- **DRUG:** Basal insulin

## Key facts

- **NCT ID:** NCT07224321
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-04
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224321, "INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07224321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*